Lifting the ‘Breakthrough’ Veil: FDA Increases Transparency To Reduce Futile Requests

FDA is hoping that greater transparency around the “breakthrough therapy” designation process will reduce the number of time-consuming, frivolous requests it receives for the coveted designation.

Much of the resource drain created by the breakthrough program results from having to evaluate requests for designation that are “not even in the ballpark,” Office of New Drugs Director...